INTRODUCTION
Acquired tracheal stenosis (ATS) is an unusual disease which main causes are related to mechanical stress by endotracheal intubation or tracheostomy tubes. Burns, trauma, previous surgery, and infectious or autoimmune inflammatory diseases may also be responsible for ATS. 1 Since the initial experience reported by McDonald and Stocks 2 regarding extended endotracheal intubation as a way of ventilatory support in preterm neonates, the incidence of airway stenosis in children has increased substantially. 3 A long-standing cuffed endotracheal tube may cause mucosal damage and secondary scarring resulting in ATS. The histologic changes observed in the mucosa include inflammation, granulation tissue formation, and fibrosis with subsequent narrowing of the tracheal lumen. 4 The type of treatment to be instituted in a patient with ATS depends on the severity, morphologic type of the lesion, and the etiologic factors. An obstruction of 50% or more of the tracheal lumen is definitely symptomatic and requires surgical or endoscopic therapy. In selected cases, tracheal resection of the stenosis with end-to-end anastomosis may offer a good and permanent result. Endoscopic procedures, such as balloon dilation, laser photoresection, or stenting may be indicated in selected cases. Overall, treatment failure for both surgical and endoscopic treatment may vary between 9% and 43% in different studies due to severe complications Additional supporting information may be found in the online version of this article.
From the Servicio de Cirug ıa Pedi atrica (J.L.A-P.); the Servicio de Cirug ıa Tor acica (I.M., A.P.G.); the Servicio de Anatom ıa Patol ogica (J.L.R-P.), Hospital such as anastomotic dehiscence, re-stenosis, airway perforation, bleeding, or tracheoesophageal fistula. [5] [6] [7] The role of medical therapy is less clear. Local treatments with corticoids or mitomycin C have been empirically tried with variable results. 8, 9 Therefore, the study of the specific factors involved in the development of granulation tissue and fibrosis causing ATS may help to identify potential therapeutic targets. Although the precise pathomechanism is not known, a general response to injury or mechanical stress to the respiratory epithelium involves selective release of transforming growth factor-b1 (TGF-b1), 10 one of the key molecular factors involved in fibrogenesis. 11, 12 Several cellular and molecular pathways such as M2 macrophage dysregulation or activation of the interleukin-17 axis may initiate the process leading to excessive fibroproliferative responses, an emerging target for intervention. [13] [14] [15] TGF-b signals through specific receptors that trigger a specific intracellular signaling cascade, leading to phosphorylation and activation of SMAD proteins. phosphorilated Smad2/3 (p-Smad2/3) form a heteromeric complex with Smad4 and translocate into nucleus where they act as specific transcription factors, initiating normal or pathological scarring responses. 16, 17 Therefore, p-Smad detection is a surrogate marker for TGF-b activation and response. TGF-b response involves differentiation of stromal cells into high extracellular matrix extracellular matrix-secreting myofibroblasts, characterized by smooth muscle cell a-actin (a-SMA) expression. 18, 19 TGF-b also induces the expression of connective tissue growth factor (CTGF) gene, a cysteine-rich protein that further enhances the profibrotic effects of TGF-b and is expressed in most fibrotic conditions. [20] [21] [22] Therefore, TGF-b represents a potential therapeutic target in different fibrotic conditions. TGF-b antagonistic antibodies or peptides have shown antifibrotic activity in a variety of experimental models of fibrosis. [23] [24] [25] [26] [27] Several animal models for ATS secondary to different types of trauma that reproduce the formation of a granulation tissue with subsequent fibrosis and stenosis have been described. [28] [29] [30] We aim to identify the participation of TGF-b signaling in the pathologic process of human and experimental ATS, and to evaluate the capacity of a TGF-b peptide antagonist to reduce fibrosis and tracheal stenosis in an animal experimental model.
MATERIALS AND METHODS

Ethics Statement
All human and animal procedures were approved by Clinical Research Committee and Animal Care and Use Committee of Hospital 12 de Octubre with protocol reference number PI12/ 00646, and carried out in accordance with the institutional guidelines.
Patients
Human tracheobronchial tissues were obtained by excision of stenotic lesions during elective therapeutic intervention of seven pediatric or young adult patients with benign ATS (67% male and mean 6 standard deviation [SD] age 20 6 7 years [11-28 years old]). Normal tracheobronchial tissues were obtained from nine pulmonary resection specimens indicated by nontracheal pathology (78% male and mean 6 SD age 63 6 4 years [58-70 years old]).
Animal Model
We developed a model of tracheal stenosis in adult New Zealand White rabbits (Granja cun ıcola San Bernardo, Navarra, Spain). Briefly, an incomplete transverse incision of the trachea was performed under anaesthesia, followed by a circumferential thermal injury to the mucosa with electrocauterization and suture. At 4 weeks, the tracheal segment was excised, fixed in formaldehyde 4% solution, and paraffin embedded. In preliminary sequential studies from 2 to 12 weeks after the intervention, the maximal stenosis was observed in rabbits sacrificed at 4 weeks.
To determine the degree of stenosis, the luminal areas at the site of injury and at the first distal noninvolved tracheal ring were photographed and the stenotic/normal luminal area ratio calculated using ImageJ software (http://rsb.info.nih.gov/ij).
For the intervention study, a total of 40 rabbits were divided into two groups (saline and TGF-b peptide antagonist p17 treatment). In addition, a group of 10 rabbits was used as control of the surgical procedure.
Histology and Immunohistochemistry
Submucosal fibrosis was evaluated as the maximal thickening of the submucosal collagen stained tissue on Masson's trichrome stained tracheal sections, which was measured using ImageJ software. Tracheas were also stained with Safranin O to assess biochemical and structural integrity of cartilage.
Immunohistochemistry (IHC) was performed on deparaffinized and rehydrated tissues after microwave heating in 1mM EDTA pH8 for antigen retrieval. Immunoperoxidase labeling was performed with mouse monoclonal anti-a-SMA antibody (1A4 clone, Sigma-Aldrich Qu ımica, Madrid, Spain), rabbit polyclonal anti-pSmad2/3 antibody, and goat polyclonal L20 anti-CTGF antibodies (Santa Cruz Biotechnology, CA) and developed by diaminobenzidine chromogen (Vector Laboratories, Burlingame, CA). Rabbit and human tissues were stained with a-SMA and CTGF antibodies, whereas pSmad2/3 antibody could only specifically recognize pSmad2/3 in human tracheal sections.
Immunostained sections were visualized on a Zeiss Scope.A1 microscope, and photographed and digitalized using an AxioCam ERc 5S camera and ZEN lite 2012 software (Zeiss, Jena, Germany). The number of a-SMA and CTGF positive cells per area were determined.
Local Treatment With p17 TGF-b Antagonist
To confirm the involvement of TGF-b in the rabbit experimental model of tracheal stenosis, a peritracheal collagen sponge containing a peptide antagonist of TGF-b p17 (2mg/mL) or control vehicle (0.9% saline) was sutured around the trachea after anastomosis. p17 is a soluble hydrophilic peptide derived from a phage display peptide library. It is capable of blocking the effects of TGF-b1 both in vitro and in vivo and has demonstrated antifibrotic activity across different species. 24, [31] [32] [33] [34] [35] [36] Four weeks after the surgical procedure, rabbits were sacrificed and tracheas were excised and paraffin-embedded for histological studies. 
Statistical Analysis
RESULTS
Human Tracheal Stenotic Tissue Show Features of TGF-b-Driven Fibrosis
To analyze the histopathological changes in the tracheobronchial tissue of patients with benign airway stenosis, we compared stenotic specimens with normal control tracheobronchial tissues. Histological examination confirmed an extensive submucosal fibrotic component, with an enhanced collagen stained area, as well as a variable inflammatory cell infiltration and epithelial hyperplasia in all cases of tracheal stenosis (Fig. 1) .
To obtain evidence of TGF-b participation in the human submucosal fibrotic lesions, we analyzed by IHC the expression of several surrogate markers of TGF-b signaling. We first compared the presence of nuclear p-Smad2/3 in stenotic versus normal tracheobronchial tissues. In normal control tracheas, p-Smad2/3 positive nuclei were rarely observed, whereas in stenotic tissues a significant increase of p-Smad2/3 positive nuclei was observed in both tracheal epithelial and submucosal cells (Fig. 1) .
The expression of the TGF-b inducible pro-fibrotic factor CTGF was also significantly increased in stenotic compared to normal tracheobronchial tissues. Whereas normal trachea showed minimal or absent CTGF immunostaining, an important increase in the number of CTGF-expressing cells, most with stromal cell shape, were observed in the submucosal fibrotic connective tissue (Fig. 1) .
Finally, the presence of a-SMA 1 myofibroblasts was analyzed. In normal tracheobronchial tissues, only vascular and smooth muscle structures showed a-SMA 1 expression. In stenotic tissues, an abundant infiltrate by a-SMA 1 cells with stromal shape consistent with myofibroblasts was observed in the submucosal fibrotic area (Fig. 1) .
The Rabbit Model of Tracheal Stenosis Reproduces the Human Fibrotic Process
Rabbit tracheal tissues undergoing surgical procedure showed a progressive luminal stenosis from 2 to 4 weeks that tended to spontaneously decrease at 12 weeks (Supp. Fig. S1 ). Tracheal stenosis was histologically characterized by a prominent fibrotic response in the submucosa, with a significant thickened collagen stained area by Masson's trichrome (Fig. 2) . Safranin O staining showed cartilage damage in stenotic areas as patchy areas of reduced cartilage thickness and weaker proteoglycan staining (Supp. Fig. S2 ). In addition, epithelial hyperplasia and an abundant inflammatory infiltrate, mainly composed by mononuclear and mast cells, were evident in the stenotic lesion (Fig. 2) . A significant increase in the number of a-SMA 1 myofibroblasts and CTGF 1 cells per area were also observed in stromal cells of stenotic tracheal tissues compared to control group (Fig. 2) .
Effect of TGF-b Antagonist on Experimental Tracheal Stenosis
To evaluate the potential contribution of TGF-b to the development of submucosal fibrosis and tracheal stenosis, rabbits were treated with peritracheal collagen sponges containing the TGF-b inhibitor p17 peptide or vehicle control. Thirty-four of 40 rabbits were analyzed at 4 weeks. The rest were excluded due to early mortality or signs of local infection. To quantify fibrosis, we measured the maximal thickness of the submucosal collagen stained area, which was significantly reduced in the p17-treated compared to the saline-treated group (Fig. 3) . The densities of a-SMA 1 myofibroblasts and CTGF 1 cells per mm 2 were significantly reduced by p17 treatment (Fig. 3) . Focal areas of reduced proteoglycan staining and reduced cartilage thickness were similarly observed in the p17 and the control group (Supp. Fig. S2 ).
The degree of luminal stenosis was evaluated in both groups of rabbits as the stenotic/normal luminal area ratio. Despite the observed reduction in fibrosis, we did not observe a significant increase in the luminal area in the p17-treated compared to the saline-treated group (Fig. 4A and 4B ). Because this data suggested that stenosis did not improve as much as the fibrotic component, we analyzed the correlation between both variables, the collagen thickness, and the luminal area. Although there was a trend to negative correlation between the luminal area and collagen thickness, the correlation coefficient was low (r 5 0.29) and nonsignificant ( Fig. 4C ).
DISCUSSION
The investigation of the mediators involved in the development of the granulation tissue and fibrotic response responsible for the development of ATS is relevant to the identification of targets of pharmacological therapies. Nonspecific antiinflammatory strategies such as glucocorticoids have shown a limited therapeutic impact 5, 37 ; therefore, more specific therapeutic targets are needed. However, obtaining mechanistic information is being limited by human tissue availability, and data from appropriate animal models are also scarce.
Previous studies have identified an important submucosal fibrotic component in stenotic lesions that may be the end result of the activation of specific inflammatory pathways. [13] [14] [15] However, the pathogenic relevance of common profibrotic mediators such as the TGF-b profibrotic pathway had not been addressed. Increased expression of TGF-b and VEGF in stenotic lesions has been described. [38] [39] [40] TGF-b could be directly induced by mechanical pressure on the respiratory epithelium, as suggested by data in cultured bronchial epithelial cells, providing a link between mechanical stress and the inflammatory and stenotic response. 38 Our data confirm that there is an important fibrotic component in tracheal stenotic lesions where all surrogate markers of TGF-b signaling are present (p-Smad, CTGF, and a-SMA). In addition, these features were reproduced in the animal model of tracheal stenosis. After the surgical procedure, rabbit tracheal tissues showed marked submucosal fibrosis accompanied by an increase CTGF expression and a-SMA 1 myofibroblasts. Therefore, this animal model provides a valid preclinical to test the impact of TGF-b antagonist.
We used a peptide antagonist of TGF-b that has demonstrated its ability to reduce fibrosis across different species by interfering the binding of TGF-b to its receptors in vivo. p17 has shown potent antifibrotic effects by interfering TGFb1 and b2 activity in a variety of animal models, either by systemic or local application. 24, 26, 27, [34] [35] [36] Although local application by direct surgical implantation of collagen sponges containing p17 is not a feasible strategy to treat human stenosis, it guaranteed inhibitor availability in this proof of concept study. Because the release of active peptide to tracheal tissue is difficult to determine, a large excess of p17 was empirically used, considering data from previous local and systemic studies. We assume efficient delivery because it resulted into significant reduction of fibrosis, but perhaps higher concentrations could have a higher impact on tracheal stenosis.
Our data provide consistent evidence on the role of TGF-b in the pathogenesis of tracheal fibrosis. p17 showed significant antifibrotic effects associated with a decreased expression of a-SMA and CTGF, two processes directly induced by TGF-b. However, the significantly reduced accumulation of fibrotic tissue in tracheal submucosa was not accompanied by an improvement in the luminal tracheal stenosis. This suggests that other components such as inflammation, epithelial hyperplasia, or structural changes like cartilage damage might contribute to the reduced tracheal lumen and remain unmodified despite anti-TGF-b effects on fibrosis. Indeed, we confirmed a poor and nonsignificant correlation between the degree of fibrosis and the tracheal luminal area in the rabbit experimental model.
CONCLUSION
In summary, our data show evidence of the relevance of TGF-b in the pathogenesis of fibrosis in a human and an animal model of ATS but also an insufficient therapeutic effect of a TGF-b blocking strategy, suggesting that the fibrosis is only a partial contributor to the reduction of the tracheal lumen in ATS.
